A FUNDAMENTAL AND CLINICAL STUDY OF CEFTIZOXIME IN THE FIELD OF OBSTETRICS AND GYNECOLOGY

A fundamental and clinical study of ceftizoxime (CZX), a new cephalosporin antibiotic, has brought about the following results. 1. The antibacterial activity of CZX against Bacteroides fragilis and B. thetaiotaomicron was superior to that of CEZ, but inferior to that of CFX.CZX was the most active o...

Full description

Saved in:
Bibliographic Details
Published inJapanese journal of antibiotics Vol. 34; no. 11; pp. 1477 - 1484
Main Authors NINOMIYA, KEIU, HASEGAWA, YUKIO, HAMAYA, KEIKO, MASUDA, KAORUKO, NISHIO, TAKEHITO
Format Journal Article
LanguageJapanese
Published Japan Japan Antibiotics Research Association 01.11.1981
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:A fundamental and clinical study of ceftizoxime (CZX), a new cephalosporin antibiotic, has brought about the following results. 1. The antibacterial activity of CZX against Bacteroides fragilis and B. thetaiotaomicron was superior to that of CEZ, but inferior to that of CFX.CZX was the most active of the 3 drugs against B. distasonis, and was as active as CFX against B. vulgatus.The MICs of CZX against Peptococcus, Peptostreptococcus and anaerobic Streptococcus were 1.56μg/ml or lower. CEZ was more active than CZX against these anaerobic cocci. 2. The concentrations of CZX in female genital organs and retroperitoneal dead space exudate after drip infusion of 1g were high enough to fulfill the MICs of many bacterial isolates. 3. CZX administered intravenously to 9 patients in daily doses of 1-8g for 4-11 days was 100% effective. Pathogenic bacteria in 6 of the patients were eradicated in 4 and partially eradicated in 1. The other patient had no bacteriological examination ter therapy. 4. No adverse reaction was observed. From above results it is concluded that CZX must be one of the most effective antibiotics for the treatment of gynecological infections.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Report-3
ObjectType-Case Study-4
ISSN:0368-2781
2186-5477
DOI:10.11553/antibiotics1968b.34.1477